摘要
目的 观察二肽基肽酶-4抑制剂（DPP-4抑制剂）西格列汀对2型糖尿病合并早期糖尿病肾病（DN）患者肾功能的影响.方法 将74例口服降糖药物（除外DPP4抑制剂）治疗的2型糖尿病合并早期糖尿病肾病患者,随机分为西格列汀组（36例）和对照组（38例）,西格列汀组原治疗方案加用西格列汀;对照组按原治疗方案增加药物剂量或联合除DPP4抑制剂外降糖药物治疗,两组控制目标均为糖化血红蛋白（HbA1c） ＜7％.结果 治疗12周后,两组胱抑素C（CysC）、β2微球蛋白（β2-MG）水平较治疗前显著降低（P＜0.05）,但西格列汀组下降更加明显,两组间比较差异有统计学意义（P＜0.05）.结论 西格列汀能显著改善早期糖尿病肾病的肾脏损害程度.
Objective To investigate the impact of sitagliptin （dipeptidyl peptidase 4 inhibitor, DPP-4 inhibitors） on renal function of patients with early diabetic nephropathy （DN）. Methods 74 cases of early diabetic nephropathy patients with oral hypoglycemic drugs （ except DPP-4 inhibitors） treatment were randomly divided into sitagliptin group（ 36 cases） and control group （38 cases）. The sitagliptin group was given sitagliptin based on the original treatment plan, whereas the control group was treated with increasing original durg dosage or combining antidiabetic drug in addition to DPP-4 inhibitors, both control objectives were glycosylated hemoglobin（HbAlc） 〈7%. Results After 12 weeks of treatment,the level of serum CysC and β2 -MG of the two group patients were significantly decreased （ P 〈 0.05 ） , and the ther- apeutic group decreased more obvious. The difference between the two group also showed statistical signifi- cance（ P 〈 0.05 ）. Conclusion Sitagliptin can significantly improve renal damage in early diabetic nephropathy （ DN ）.
出处
《临床内科杂志》
CAS
2014年第7期474-476,共3页
Journal of Clinical Internal Medicine
